Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase

European Journal of Pharmaceutical Sciences

Volumn 29, Issue 3-4 SPEC. ISS., 2006, Pages 205-214

  Bergman, Ebba ^a   Forsell, Patrik ^b   Tevell, Annica ^c   Persson, Eva M ^a   Hedeland, Mikael ^c   Bondesson, Ulf ^a,c   Knutson, Lars ^b   Lennernäs, Hans ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c NATIONAL VETERINARY INSTITUTE   (Sweden)

Author keywords

Absorption; Biliary secretion; Intestinal intubation; Rosuvastatin

Indexed keywords

BILE ACID; ROSUVASTATIN;

ADULT; ARTICLE; BALLOON; BLOOD SAMPLING; DISPERSION; DRUG ABSORPTION; DRUG ELIMINATION; DRUG TRANSPORT; DUODENUM; FEMALE; HUMAN; HUMAN EXPERIMENT; INTESTINE PERFUSION; JEJUNUM; MALE; NORMAL HUMAN; PRIORITY JOURNAL; TUBE; VOLUNTEER;

ADULT; BILE; BILE ACIDS AND SALTS; FEMALE; FLUOROBENZENES; GALLBLADDER; HUMANS; INTESTINAL ABSORPTION; MALE; PYRIMIDINES; SULFONAMIDES;

EID: 33750192677     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.04.015     Document Type: Article

References (52)

1. Agoston S., Vermeer G.A., Kertsten U.W., and Meijer D.K. The fate of pancuronium bromide in man. Acta Anaesthesiol. Scand. 17 (1973) 267
2. Angelin B., Arvidsson A., Dahlqvist R., Hedman A., and Schenck-Gustafsson K. Quinidine reduces biliary clearance of digoxin in man. Eur. J. Clin. Invest. 17 (1987) 262
3. Arvidsson A., Alvan G., Angelin B., Borga O., and Nord C.E. Ceftriaxone: renal and biliary excretion and effect on the colon microflora. J. Antimicrob. Chemother. 10 (1982) 207
4. AstraZeneca, 2003. Crestor (Rosuvastatin) Product Monograph, 1.
5. Bonlokke L., Christensen F.N., Knutson L., Kristensen H.G., and Lennernas H. A new approach for direct in vivo dissolution studies of poorly soluble drugs. Pharm. Res. 14 (1997) 1490
6. Bonlokke L., Hovgaard L., Kristensen H.G., Knutson L., and Lennernas H. Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans. Eur. J. Pharm. Sci. 12 (2001) 239
7. Bonlokke L., Hovgaard L., Kristensen H.G., Knutson L., Lindahl A., and Lennernas H. A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans. Eur. J. Pharm. Sci. 8 (1999) 19
8. Brown C.D.A., Windass A., Bleasby K., and Lauffart B. Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C. Atherosclerosis Suppl. 2 (2001) 90
9. Caldwell J.H., and Cline C.T. Biliary excretion of digoxin in man. Clin. Pharmacol. Ther. 19 (1976) 410
10. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Raza A., and Schneck D.W. The effect of erythromycin on the pharmacokinetics of rosuvastatin. Eur. J. Clin. Pharmacol. 59 (2003) 51
11. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Raza A., and Schneck D.W. Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects. Br. J. Clin. Pharmacol. 55 (2003) 94
12. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Schneck D.W., and Cantarini M.V. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur. J. Clin. Pharmacol. 58 (2002) 527
13. Cooper K.J., Martin P.D., Dane A.L., Warwick M.J., Schneck D.W., and Cantarini M.V. Effect of itraconazole on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 73 (2003) 322
14. Fujino H., Saito T., Tsunenari Y., Kojima J., and Sakaeda T. Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors. Xenobiotica 34 (2004) 961
15. Ghibellini G., Johnson B.M., Kowalsky R.J., Heizer W.D., and Brouwer K.L.R. A novel method for the determination of biliary clearance in humans. AAPS J. 6 (2004) 1
16. Gundert-Remy U., Frohnapfel F., Jourdan W., Weber E., and Stiehl A. Estimation of biliary excretion of ureidopenicillins in healthy volunteers using marker dilution technique. Br. J. Clin. Pharmacol. 13 (1982) 795
17. Hernell O., Staggers J.E., and Carey M.C. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry 29 (1990) 2041
18. Hofmann A.F. The enterohepatic circulation of bile acids in man. Adv. Intern. Med. 21 (1976) 501
19. Knutson L., Odlind B., and Hallgren R. A new technique for segmental jejunal perfusion in man. Am. J. Gastroenterol. 84 (1989) 1278
20. Lanzini A., Jazrawi R.P., and Northfield T.C. Simultaneous quantitative measurements of absolute gallbladder storage and emptying during fasting and eating in humans. Gastroenterology 92 (1987) 852
21. Lanzini A., Pigozzi M.G., Wuhrer A., Facchinetti D., Castellano M., Bettini L., Guerra U.P., Beschi M., and Muiesan G. Quantitative measurement of biliary excretion and of gall bladder concentration of drugs under physiological conditions in man. Gut 30 (1989) 104
22. Lee W.M. Drug-induced hepatotoxicity. N. Engl. J. Med. 349 (2003) 474
23. Lennernas H., Ahrenstedt O., Hallgren R., Knutson L., Ryde M., and Paalzow L.K. Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man. Pharm. Res. 9 (1992) 1243
24. Loria P., Carulli N., Medici G., Tripodi A., Iori R., Rovesti S., Bergomi M., Rosi A., and Romani M. Determinants of bile secretion: effect of bile salt structure on bile flow and biliary cation secretion. Gastroenterology 96 (1989) 1142
25. Martin P.D., Dane A.L., Nwose O.M., Schneck D.W., and Warwick M.J. No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor. J. Clin. Pharmacol. 42 (2002) 1116
26. Martin P.D., Dane A.L., Schneck D.W., and Warwick M.J. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers. Clin. Ther. 25 (2003) 459
27. Martin P.D., Kemp J., Dane A.L., Warwick M.J., and Schneck D.W. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. J. Clin. Pharmacol. 42 (2002) 1352
28. Martin P.D., Warwick M.J., Dane A.L., Brindley C., and Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin. Ther. 25 (2003) 2553
29. Martin P.D., Warwick M.J., Dane A.L., and Cantarini M.V. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers. Clin. Ther. 25 (2003) 2215
30. Martin P.D., Warwick M.J., Dane A.L., Hill S.J., Giles P.B., Phillips P.J., and Lenz E. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin. Ther. 25 (2003) 2822
31. Meijer D.K., and Lennernas H. EUFEPS conference on drug transporters at Copenhagen: integrative approaches in ADME research. Eur. J. Pharm. Sci. 26 (2005) 130
32. Meijer D.K., Weert B., and Vermeer G.A. Pharmacokinetics of biliary excretion in man. VI. Indocyanine green. Eur. J. Clin. Pharmacol. 35 (1988) 295
33. Meijer D.K., Weitering J.G., and Vermeer G.A. Pharmacokinetics of biliary excretion in man. V. Dibromosulfophthalein. Eur. J. Clin. Pharmacol. 24 (1983) 549
34. Meijer D.K., Vermeer G.A., and Kwant G. The excretion of hexafluorenium in man and rat. Eur. J. Pharmacol. 14 (1971) 280
35. Nezasa K., Higaki K., Matsumura T., Inazawa K., Hasegawa H., Nakano M., and Koike M. Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin. Drug Metab. Dispos. 30 (2002) 1158
36. Prueksaritanont T., Subramanian R., Fang X., Ma B., Qiu Y., Lin J.H., Pearson P.G., and Baillie T.A. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab. Dispos. 30 (2002) 505
37. Prueksaritanont T., Tang C., Qiu Y., Mu L., Subramanian R., and Lin J.H. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab. Dispos. 30 (2002) 1280
38. Qadir M., O'Loughlin K.L., Fricke S.M., Williamson N.A., Greco W.R., Minderman H., and Baer M.R. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin. Cancer Res. 11 (2005) 2320
39. Qvist N., Rafaelsen S., Oster-Jorgensen E., Rasmussen L., Hovendal C., and Pedersen S.A. The simultaneous use of 99m-Tc-HIDA scintigraphy and ultrasound in the determination of gallbadder storage and emptying in the fasting state. Eur. J. Gastroenterol. Hepatol. 3 (1991) 657
40. Roberts M.S., Magnusson B.M., Burczynski F.J., and Weiss M. Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin. Pharmacokinet. 41 (2002) 751
41. Ryde M., and Gustavsson S. Biliary excretion of olsalazine sodium in humans. Eur. J. Drug Metab. Pharmacokinet. 12 (1987) 17
42. Schneck D.W., Birmingham B.K., Zalikowski J.A., Mitchell P.D., Wang Y., Martin P.D., Lasseter K.C., Brown C.D., Windass A.S., and Raza A. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. Clin. Pharmacol. Ther. 75 (2004) 455
43. Sgro C., Clinard F., Ouazir K., Chanay H., Allard C., Guilleminet C., Lenoir C., Lemoine A., and Hillon P. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36 (2002) 451
44. Shaffer E.A. Review article: control of gall-bladder motor function. Aliment Pharmacol. Ther. 14 Suppl. 2 (2000) 2
45. Shipkova M., Armstrong V.W., Oellerich M., and Wieland E. Acyl glucuronide drug metabolites: toxicological and analytical implications. Ther. Drug Monit. 25 (2003) 1
46. Simonson S.G., Raza A., Martin P.D., Mitchell P.D., Jarcho J.A., Brown C.D., Windass A.S., and Schneck D.W. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin. Pharmacol. Ther. 76 (2004) 167
47. Strasberg S.M., Harvey P.R., and Hofmann A.F. Bile sampling, processing and analysis in clinical studies. Hepatology 12 (1990) 176S
48. Sutfin T.A., Lind T., Gabrielsson M., and Regardh C.G. Biliary secretion of felodipine metabolites in man after intravenous [14C]felodipine. Eur. J. Clin. Pharmacol. 38 (1990) 421
49. Westphal J.F., Brogard J.M., Caro-Sampara F., Adloff M., Blickle J.F., Monteil H., and Jehl F. Assessment of biliary excretion of piperacillin-tazobactam in humans. Antimicrob. Agents Chemother. 41 (1997) 1636
50. Westra P., Vermeer G.A., de Lange A.R., Scaf A.H., Meijer D.K., and Wesseling H. Hepatic and renal disposition of pancuronium and gallamine in patients with extrahepatic cholestasis. Br. J. Anaesth. 53 (1981) 331
51. Wierda J.M., Szenohradszky J., De Wit A.P., Zentai G., Agoston S., Kakas M., Kleef U.W., and Meijer D.K. The pharmacokinetics, urinary and biliary excretion of pipecuronium bromide. Eur. J. Anaesthesiol. 8 (1991) 451
52. Yao L., Heubi J.E., Buckley D.D., Fierra H., Setchell K.D., Granholm N.A., Tso P., Hui D.Y., and Woollett L.A. Separation of micelles and vesicles within lumenal aspirates from healthy humans: solubilization of cholesterol after a meal. J. Lipid Res. 43 (2002) 654